Jason Butler
Stock Analyst at JMP Securities
(4.59)
# 234
Out of 4,984 analysts
140
Total ratings
51.39%
Success rate
34.1%
Average return
Main Sectors:
Stocks Rated by Jason Butler
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRTA Prothena Corporation | Maintains: Market Outperform | $29 → $11 | $8.06 | +36.48% | 11 | Sep 2, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Market Outperform | $33 → $95 | $81.00 | +17.28% | 4 | Jul 23, 2025 | |
| RAPP Rapport Therapeutics | Reiterates: Market Outperform | $28 | $26.30 | +6.46% | 2 | Jul 8, 2025 | |
| ACAD ACADIA Pharmaceuticals | Reiterates: Market Outperform | $37 | $24.20 | +52.89% | 14 | Jun 26, 2025 | |
| GHRS GH Research | Reiterates: Market Outperform | $39 | $12.50 | +212.00% | 5 | Jun 24, 2025 | |
| PGEN Precigen | Reiterates: Market Outperform | $6 | $3.82 | +57.07% | 11 | Jun 12, 2025 | |
| TTD The Trade Desk | Maintains: Market Outperform | $115 → $100 | $45.37 | +120.41% | 1 | May 9, 2025 | |
| VRDN Viridian Therapeutics | Maintains: Market Outperform | $42 → $38 | $18.62 | +104.08% | 8 | May 7, 2025 | |
| CYTK Cytokinetics | Reiterates: Market Outperform | $78 | $47.56 | +64.00% | 16 | Apr 10, 2025 | |
| ZVRA Zevra Therapeutics | Maintains: Market Outperform | $17 → $18 | $7.33 | +145.57% | 2 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $4 | $2.72 | +47.06% | 7 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $696 → $701 | $734.35 | -4.54% | 8 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $29 → $33 | $9.57 | +244.83% | 1 | Feb 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $8 → $9 | $7.71 | +16.73% | 8 | Feb 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $72 → $73 | $75.81 | -3.71% | 13 | Nov 1, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $9 | $4.83 | +86.34% | 7 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $0.38 | - | 7 | Sep 4, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Market Outperform | $19 | $11.12 | +70.86% | 6 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $22 | $1.28 | +1,618.75% | 1 | Sep 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $2.14 | - | 1 | Oct 17, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Outperform | $42,000 | $8.59 | +488,840.63% | 1 | Dec 15, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $111 → $116 | $7.54 | +1,438.46% | 4 | Nov 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Market Outperform | $7 → $9 | $4.43 | +103.16% | 1 | Nov 8, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Market Perform | n/a | $1.16 | - | 1 | Dec 2, 2020 |
Prothena Corporation
Sep 2, 2025
Maintains: Market Outperform
Price Target: $29 → $11
Current: $8.06
Upside: +36.48%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Market Outperform
Price Target: $33 → $95
Current: $81.00
Upside: +17.28%
Rapport Therapeutics
Jul 8, 2025
Reiterates: Market Outperform
Price Target: $28
Current: $26.30
Upside: +6.46%
ACADIA Pharmaceuticals
Jun 26, 2025
Reiterates: Market Outperform
Price Target: $37
Current: $24.20
Upside: +52.89%
GH Research
Jun 24, 2025
Reiterates: Market Outperform
Price Target: $39
Current: $12.50
Upside: +212.00%
Precigen
Jun 12, 2025
Reiterates: Market Outperform
Price Target: $6
Current: $3.82
Upside: +57.07%
The Trade Desk
May 9, 2025
Maintains: Market Outperform
Price Target: $115 → $100
Current: $45.37
Upside: +120.41%
Viridian Therapeutics
May 7, 2025
Maintains: Market Outperform
Price Target: $42 → $38
Current: $18.62
Upside: +104.08%
Cytokinetics
Apr 10, 2025
Reiterates: Market Outperform
Price Target: $78
Current: $47.56
Upside: +64.00%
Zevra Therapeutics
Mar 12, 2025
Maintains: Market Outperform
Price Target: $17 → $18
Current: $7.33
Upside: +145.57%
Mar 5, 2025
Reiterates: Market Outperform
Price Target: $4
Current: $2.72
Upside: +47.06%
Feb 28, 2025
Maintains: Outperform
Price Target: $696 → $701
Current: $734.35
Upside: -4.54%
Feb 21, 2025
Maintains: Market Outperform
Price Target: $29 → $33
Current: $9.57
Upside: +244.83%
Feb 13, 2025
Maintains: Market Outperform
Price Target: $8 → $9
Current: $7.71
Upside: +16.73%
Nov 1, 2024
Maintains: Market Outperform
Price Target: $72 → $73
Current: $75.81
Upside: -3.71%
Oct 8, 2024
Reiterates: Market Outperform
Price Target: $9
Current: $4.83
Upside: +86.34%
Sep 4, 2024
Downgrades: Market Perform
Price Target: n/a
Current: $0.38
Upside: -
Apr 9, 2024
Reiterates: Market Outperform
Price Target: $19
Current: $11.12
Upside: +70.86%
Sep 28, 2023
Initiates: Market Outperform
Price Target: $22
Current: $1.28
Upside: +1,618.75%
Oct 17, 2022
Downgrades: Market Perform
Price Target: n/a
Current: $2.14
Upside: -
Dec 15, 2021
Initiates: Market Outperform
Price Target: $42,000
Current: $8.59
Upside: +488,840.63%
Nov 23, 2021
Maintains: Market Outperform
Price Target: $111 → $116
Current: $7.54
Upside: +1,438.46%
Nov 8, 2021
Maintains: Market Outperform
Price Target: $7 → $9
Current: $4.43
Upside: +103.16%
Dec 2, 2020
Downgrades: Market Perform
Price Target: n/a
Current: $1.16
Upside: -